Market capitalization | $61.00m |
Enterprise Value | $-44.24m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.23 |
EV/Sales (TTM) EV/Sales | -3.83 |
P/S ratio (TTM) P/S ratio | 5.28 |
P/B ratio (TTM) P/B ratio | 0.73 |
Revenue (TTM) Revenue | $11.56m |
EBIT (operating result TTM) EBIT | $-235.00m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Adagio Therapeutics Inc forecast:
4 Analysts have issued a Adagio Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 12 12 |
-
|
|
Gross Profit | 8.56 8.56 |
598%
598%
|
|
EBITDA | -233 -233 |
34%
34%
|
EBIT (Operating Income) EBIT | -235 -235 |
34%
34%
|
Net Profit | -225 -225 |
33%
33%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
Head office | United States |
CEO | William Duke |
Employees | 94 |
Founded | 2020 |
Website | invivyd.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.